CHRS Coherus BioSciences Inc.

Coherus BioSciences to Present at Upcoming Investor Conferences in March

Coherus BioSciences to Present at Upcoming Investor Conferences in March

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March.

  • 43rd Annual Cowen Health Care Conference on Tuesday, March 7th at 2:10 p.m. ET
  • Barclays 2023 Global Healthcare Conference on Tuesday, March 14th at 4:05 p.m. ET

Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. Each webcast will be archived on the Coherus website for 30 days.

Coherus Contact Information:

Marek Ciszewski, SVP Investor Relations

 



EN
01/03/2023

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTOR...

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi)...

December 8, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data fo...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody – CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot” REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor an...

November 7, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Reports Third Quarter 2025 Financial Results and Prov...

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update – CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 an...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Aff...

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood’s responsibilities include key externally facing and strategic functions. “We are thrilled to have a such a well-regarded senior biotechnology executive j...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Third Quarter 2025 Financial Results on Nov...

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Con...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch